Christopher Hite

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Cambridge, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Sean Weisberg, as Attorney-in-Fact for Christopher Hite
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Christopher Hite

Form 4 holding EVP & Chairman, Partnering

Royalty Pharma plc

Security class
LP interests in RPI US Partners 2019, LP
Shares / value
86,641
Estimated value
Report date
14 Feb 2025
Price
Ownership
By SCH Investment Partners LLC
Underlying class
Class A Ordinary Shares
Underlying amount
Form 4 holding Director

Kailera Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
38,300
Estimated value
Report date
16 Apr 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

ACCELERON PHARMA INC

Security class
Common Stock
Shares / value
0
Estimated value
Report date
19 Nov 2021
Price
$29.37
Ownership
Direct
Form 4 holding Director

ACCELERON PHARMA INC

Security class
Option to Purchase Common Stock
Shares / value
0
Estimated value
Report date
19 Nov 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Christopher Hite

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .